A 6-Month, Double-Blind, Placebo-Controlled, Multi-Center, Parallel Group, Maintenance Of Effect Study Of Esreboxetine (PNU-165442g) Administered Once Daily (QD) In Patients With Fibromyalgia.
Withdrawn prior to enrolment
Phase of Trial: Phase III
Latest Information Update: 04 Mar 2015
At a glance
- Drugs Esreboxetine (Primary)
- Indications Fibromyalgia
- Focus Therapeutic Use
- Sponsors Pfizer
- 18 Aug 2012 Actual initiation date (14 Jan 2009) added as reported by European Clinical Trials Database.
- 17 Mar 2009 Status changed from not yet recruiting to withdrawn prior to recruitment, as reported by clinicaltrials.gov.
- 25 Feb 2009 Pfizer has decided to discontinue development of this drug, as reported in a media release.